Autoinflammatory & rare systemic diseases
Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response
Authors' conclusion
Sarcoidosis patients treated with abatacept and tofacitinib had long drug survival, achieved high response rates.
Study context
- Population
- Sarcoidosis patients treated with abatacept or tofacitinib in routine care; nearly all previously treated with at least one TNFi
- Participants
- 41 vs 12
- Exposure
- Abatacept and tofacitinib
- Abataceptn = 41
- Tofacitinibn = 12
- Outcome
- Drug survival
Methodological detailsroutine care, no direct comparison of drugs
- Routine care
- No direct comparison of drugs
Main finding
As reported in the abstract
Drug survival (maintained treatment) · 6 months
Observational data: associations, not effects.
Further findings
Responders (within first 6 months)
Prednisolone dosage and soluble IL2-receptor levels · all time points
- Significant reduction in both treatment groups
Safety
- No serious adverse events were recorded
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response. Clin Exp Rheumatol. Published 8 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →